The in vitro activities of two new beta-lactam antibiotics, cefotaxime and moxalactam (LY127935), were compared with those of cefamandole, cefoxitin, cefuroxime, and ampicillin against both beta-lactamase-producing and non-betalactamase-producing isolates of Haemophilus influenzae. Both cefotaxime and LY127935 were highly active against all isolates irrespective of beta-lactamase production.
Since the emergence of ampicillin resistance among strains of Haemophilus influenzae in 1972 (3, 7) , considerable emphasis has been placed upon development of newer antibiotics that might prove useful against these microorganisms. The findings of a national survey (9) have indicated the current prevalence of ampicillin resistance in H. influenzae to be approxi: mately 4.5% in the United States. Although chloramphenicol resistance has been reported clude beta-lactamase producers of the; Enterobacteriaceae and Pseudomonadaceae families (6, 8, 10) . In this study, we compared the in vitro activities of cefotaxime and LY127935 with those ofcurrent-generation beta-lactam antibiotics, including cefamandole, cefoxitin, cefuroxime, and ampicillin. Eighty isolates of H. influenzae (most of which were type b), including 27 betalactamase producers, were tested by an agar dilution procedure using Mueller-Hinton agar Cefotaxime (HR 756) and moxalactam (LY127935) are two new beta-lactam compounds with broad in vitro spectra, which inand 5% Supplement C (1). An inoculum of approxiinately 104 microorganisms was applied to the surface of the agar plates with a Steers inoculum replicating device. All susceptibility tests were incubated for 24 h at 350C in a 3 to 5% CO2 atmosphere. The miniimal inhibitory concentration was defined as the lowest concentration of antibiotic that prevented visible growth on the surface of the agar or allowed growth of no more than three colonies. Produc-tion of beta-lactamase was determined on all strains by use of a rapid iodometric paper strip test (2) .
Results of agar dilution susceptibility and beta-lactamase tests are depicted in Table 1 . Cefotaxime was the most active antibiotic tested against both beta-lactamase and non-beta-lactamase producers. Ninety percent of all isolates were inhibited by 0.03 ,ug or less of cefotaxime per ml. LY127935 was found to be only slightly less active than cefotaxime against both groups of isolates (90% miniimal inhibitory concentration, 0.06 Ag/ml). The next most active drug was cefuroxime (90% minimal inhibitory concentration, 1 ug/ml), followed by cefamandole and cefoxitin, which were found to have approximately 1 dilution increment less activity against the beta-lactamase-producing strains than those that did not produce the enzyme. Ampicilhin inhibitory activity was directly related to the presence or absence ofbeta-lactamase; very good activity was seen against those isolates that did not produce beta-lactamase.
Both cefotaxime and LY127935 demonstrated impressive in vitro activity against both betalactamase-producing and non-beta-lactamaseproducing isolates of H. influenzae in this study.
Both drugs were markedly more active than ampicillin against all strains regardless of betalactamase production. The results obtained in this study with cefotaxime compare favorably with those reported by Van Landuyt and Pyckavet (8) and Wise et al. (10) . The broad antibacterial spectra of both compounds provide great promise for therapy of a variety of infectious processes, including those due to H. influenzae.
Both drugs are considerably more active than currently available cephamycin-or cephasporinclass agents.
